Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

HER2 Positive Breast Cancer × pertuzumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 180 HER2-positive Breast Cancer 18 Neoplasms 13 Neoplasm Metastasis 11 Prostatic Neoplasms 7 Ovarian Neoplasms 7 Stomach Neoplasms 6 Carcinoma, Non-Small-Cell Lung 6 Pancreatic Neoplasms 5 Inflammatory Breast Neoplasms 5 Colonic Neoplasms 5 Brain Neoplasms 5 Triple Negative Breast Neoplasms 4 Multiple Myeloma 4 Hematologic Neoplasms 4 Endometrial Neoplasms 4 Colorectal Neoplasms 4 Urinary Bladder Neoplasms 3 Solid Tumor 3 Rectal Neoplasms 3 Pathologic Complete Response 3 Lymphoma, Non-Hodgkin 3 Lung Neoplasms 3 HER2-positive Early Breast Cancer 3 Esophageal Neoplasms 3 Breast Neoplasms, Male 3 Biliary Tract Neoplasms 3 Anatomic Stage I Breast Cancer AJCC v8 3 Salivary Gland Neoplasms 2 Locally Advanced Breast Cancer 2

Interventions

Trastuzumab 4 pyrotinib 3 Vinorelbine 2 pertuzumab 1 copanlisib 1 Lapatinib 1 Docetaxel 1 Carboplatin 1 Capecitabine 1 Ado-Trastuzumab Emtansine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01904903 2022-05-10

SAFE-HEaRt

Medstar Health Research Institute

Phase 2 Completed

31 enrolled 12 charts

HER2 Positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡